Dianthus Therapeutics, Inc. (DNTH)
82.37
-0.06
(-0.07%)
USD |
NASDAQ |
Oct 09, 16:00
83.00
+0.63
(+0.76%)
After-Hours: 20:00
Dianthus Therapeutics Profit Margin (Quarterly) : -6.60K% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.60K% |
| March 31, 2026 | -8.82K% |
| December 31, 2025 | -22.69K% |
| September 30, 2025 | -9.28K% |
| June 30, 2025 | -16.39K% |
| March 31, 2025 | -2.54K% |
| December 31, 2024 | -2.14K% |
| September 30, 2024 | -1.16K% |
| Date | Value |
|---|---|
| June 30, 2024 | -945.1% |
| March 31, 2024 | -1.57K% |
| December 31, 2023 | -2.31K% |
| September 30, 2023 | -1.60K% |
| June 30, 2023 | -1.15K% |
| March 31, 2023 | -1.49K% |
| December 31, 2022 | -860.9% |
| September 30, 2022 | -663.6% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Verastem, Inc. | -86.51% |
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Anika Therapeutics, Inc. | 10.15% |
| Savara, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -25.87% |
| Return on Assets | -24.68% |
| Return on Invested Capital | -25.82% |
| Gross Profit Margin (Quarterly) | 85.94% |
| Operating Margin (Quarterly) | -8.08K% |
| Return on Net Operating Assets | -1.93K% |